matdesign24/iStock via Getty Images
- Merck (MRK) and Gilead Sciences (GILD) said that topline results from a pair of phase 3 trials of a combination pill containing the former’s islatravir and the latter’s lenacapavir met their primary endpoint.
- The two studies, ISLEND-1 and ISLEND-2 trial, are testing
